More on MIRM

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-1,080.0% Growth)
- Ratings (10.0 Score)
- Holders

Upcoming Events

- Earnings (11/17/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Mirum Pharmaceuticals, Inc. (NQ:MIRM)
Delayed: 81.22 +1.08 (1.35%)
Prev. Close $80.14  
Open$80.90 
52 Wk High$ 
52 Wk Low$ 
Day High$81.69 
Day Low$80.35 
P/E N/A  
EPS$ 
Volume34,775 

Friends, Peers and Foes (?): INCY, UTHR, XENE, VRTX, VIR (more...)

Oct 15, 2026 04:01 PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 15, 2026 09:34 AM Mirum Pharmaceuticals (MIRM) PT Raised to $156 at Stifel on Clinical/Regulatory Wins
Oct 14, 2026 04:07 PM Form 4 Mirum Pharmaceuticals, For: Oct 09 Filed by: Myers Robert Paul
Oct 13, 2026 08:09 AM Form 8-K Mirum Pharmaceuticals, For: Oct 12
Oct 13, 2026 05:18 AM Mirum Pharmaceuticals (MIRM) PT Raised to $152 at Morgan Stanley
Oct 12, 2026 01:57 PM Mirum Pharmaceuticals (MIRM) PT Raised to $184 at Citi
Oct 12, 2026 10:43 AM Raymond James on Mirum Pharmaceuticals (MIRM): 'we think its ~$1B+ estimate for the Livmarli opportunity is continuing to look more and more conservative'
Oct 12, 2026 09:42 AM Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease
Oct 12, 2026 09:36 AM TD Cowen on Mirum Pharmaceuticals (MIRM): 'We continue to view shares as undervalued'
Oct 12, 2026 09:34 AM Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock'
View All Articles

Entities mentioned with MIRM

View All Entities